In:
Cardiovascular Therapeutics, Wiley, Vol. 34, No. 6 ( 2016-12), p. 460-467
Kurzfassung:
To investigate the correlations of three P2Y12 receptor (P2Y12R) gene polymorphisms (rs7428575 T 〉 G, rs2046934 C 〉 T, and rs3732759 A 〉 G) with susceptibility to coronary artery disease ( CHD ) and clinical efficacy of clopidogrel treatment for CHD . Methods From May 2014 to May 2015, 178 CHD patients (the case group) and 182 healthy controls (the control group) were selected from our hospital. The platelet‐rich plasma ( PRP ) turbidimetry was used to measure the rate of adenosine diphosphate ( ADP )‐induced platelet aggregation before and after clopidogrel treatment. Clopidogrel‐sensitive group was defined as a 10% or greater decrease in the rate of platelet aggregation after 10 days of clopidogrel treatment, while clopidogrel‐resistant group was defined as a 〈 10% decrease. Genotyping was performed by denaturing high‐performance liquid chromatography ( DHPLC ). A haplotype analysis of P2Y12R gene polymorphisms was performed using SHE sis software. Results There were significant differences in genotype and allele frequencies of rs2046934 C 〉 T and rs3732759 A 〉 G between the case and control groups (all P 〈 .05). Haplotypes GTA and TTA were negatively associated with CHD risk (both P 〈 .05), but haplotype TCA was positively associated with CHD risk ( P =.005). CHD patients in the clopidogrel‐sensitive group had higher frequencies of TT genotype of rs2046934 C 〉 T and lower frequencies of GG genotype of rs3732759 A 〉 G than those in the clopidogrel‐resistant group (both P 〈 .05). Conclusions P2Y12R gene rs2046934 C 〉 T and rs3732759 A 〉 G polymorphisms might be associated with the risk of CHD and the efficacy of clopidogrel treatment for CHD .
Materialart:
Online-Ressource
ISSN:
1755-5914
,
1755-5922
DOI:
10.1111/cdr.2016.34.issue-6
DOI:
10.1111/1755-5922.12223
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2016
ZDB Id:
2417088-4
